START's Expansion Strengthens Global Urologic Research Network

START Strengthens Its Global Network with CURC Acquisition

START's Site Network Enhances Leadership in Urological Cancer Trials

The START Center for Cancer Research ("START"), a prominent authority in early-phase oncology clinical trials, has recently expanded its global network by acquiring Carolina Urologic Research Center ("CURC"), a leading site specializing in genitourinary (GU) oncology. This strategic move is aimed at bolstering START's capabilities in one of the most rapidly evolving areas of cancer research. GU cancers are increasingly prevalent, with an estimated 2.6 million new cases diagnosed annually, accounting for more than one in eight cancer diagnoses worldwide.

Integration of Specialized Capabilities

Founded in 1998 by Dr. Neal Shore, MD, FACS, CURC has played a pivotal role in conducting nearly 500 clinical trials, solidifying its status as the premier urologic oncology site globally in both volume and quality. CURC’s established expertise in both early- and late-phase trials equips START with valuable scientific insights and leadership for its extensive research portfolio.

A Dedicated Center of Excellence

In conjunction with the integration of CURC, START is establishing a dedicated Center of Excellence (COE) that will focus on providing comprehensive trial solutions for urological cancers. This COE is designed to bridge the existing gap between research innovations and clinical applications by integrating both early and late-phase trial executions with direct patient-to-PDX translational services, ultimately enhancing the research-to-treatment continuum.

Impact on Urological Cancer Research

Dr. Neal Shore will lead the COE in driving innovation within the realm of urologic oncology. This initiative will amplify START’s partnerships with top-tier urological practices globally, ensuring sponsors have access to a fully integrated, end-to-end solution that expedites the development and delivery of breakthrough therapies to patients.

Nick Slack, MBE, Chairman and CEO of START, emphasizes the significance of this expansion, stating, "Urologic cancers are among the fastest-growing sectors in oncology, driven by different factors such as an aging population, rising incidence rates, and improvements in diagnostic methods. We are committed to facilitating research opportunities that allow patients to access the most advanced therapeutic options available today. CURC’s exceptional standing, strong sponsor relations, and deep insights will greatly enhance our integration and growth within this vital area.”

Commitment to Patient-Centric Innovations

Dr. Neal Shore, Founder and Medical Director of CURC, expressed enthusiasm about joining the START network: "This partnership marks an exciting evolution for CURC. As a leader in early-phase oncology trials, START shares our dedication to delivering the benefits of clinical trials to patients across the globe. By becoming part of the START network, we will gain access to enhanced expertise and resources, effectively expanding our influence on urologic oncology research. Together, we strive to create greater opportunities for patients, sponsors, and investigators alike.”

About START

START is firmly established within community oncology centers worldwide, providing unique access to specialized preclinical and early-phase clinical trials of innovative anti-cancer agents. With over a thousand early-phase trials conducted, including numerous therapies that have received FDA or EMA approval, START boasts the most extensive roster of Principal Investigators (PIs) across its eight clinical trial sites. It is profoundly dedicated to facilitating the transition from trials to treatments, fulfilling the hopes of patients, families, and healthcare professionals globally.

About Carolina Urologic Research Center

Carolina Urologic Research Center (CURC) is well-regarded both nationally and internationally as a top-tier clinical research site within the United States. CURC employs a highly skilled team of healthcare professionals, which includes 6 board-certified urologists and 22 experienced research staff, allowing it to participate in approximately 500 national and international clinical research trials dedicated to various urologic conditions over the last 25 years.

Frequently Asked Questions

What is the significance of START's acquisition of CURC?

This acquisition enhances START's capabilities in urological cancer research, providing greater access to expertise, resources, and clinical trial solutions.

How many clinical trials has CURC conducted?

CURC has been involved in nearly 500 clinical trials, making it a leading site in urologic oncology globally.

What will the Center of Excellence focus on?

The Center of Excellence will specialize in urological cancers, integrating trial solutions and accelerating the development of novel therapies for patients.

Who leads the Center of Excellence?

Dr. Neal Shore, the founder of CURC, will lead the Center of Excellence and drive the initiative to enhance innovation in urologic oncology.

What does START aim to achieve through this expansion?

START aims to lead research in urological cancers, ensuring patients have access to advanced therapeutic options while continuing to innovate in clinical trial methodologies.

About The Author

Hello, I'm 30-year-old financial writer and expert Addison Perry, and I love to simplify the intricacies of the financial industry. I've committed myself over the years to deciphering the subtleties of investing techniques and economic trends and converting them into doable guidance that anybody can use. My goal with writings and books is to make money interesting and approachable so that readers may take charge of their financial futures.

My enthusiasm to empowerment and education has propelled me through my career in finance. I write because I think that everyone should be able to make educated financial decisions, and I try to provide that. Regardless of experience level with investing, my work is intended to provide insightful analysis and practical advice to enable you to thrive in the always changing financial environment. I appreciate you traveling with me toward success and financial literacy.

Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.